Overview

Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia

Status:
Terminated
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the safety and tolerability profile of ITI-214 when administered as multiple doses of oral solution at escalating dose levels.
Phase:
Phase 1
Details
Lead Sponsor:
Takeda
Collaborator:
Intra-Cellular Therapies, Inc.
Treatments:
Pharmaceutical Solutions